Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Saved in:
Main Authors: | Leisha A Emens, Huilin Ma, Hanwen Wang, Richard J Sové, Aleksander S Popel |
---|---|
Format: | article |
Language: | EN |
Published: |
BMJ Publishing Group
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/46662a33a2a04b4e89ceddf01ba602a9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Published: (2021) -
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
by: Julia Foldi, et al.
Published: (2021) -
Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
by: Sun S, et al.
Published: (2014) -
Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
by: Yizhao Xie, et al.
Published: (2021) -
Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel–cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines
by: Ye J, et al.
Published: (2016)